Sotrovimab is much less effective against BA.2... - CLL Support
Sotrovimab is much less effective against BA.2 sub variant - possibly 27 times less effective.
You need to be a member of this community to see this post.
Read more about...
9 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
COVID-19 hospitalizations soaring in England.
The UK is assuming that COVID-19 is endemic and that Omicron is mild. But the confluence of BA.2...
The failing effectiveness of COVID-19 monoclonal antibodies against BA.1, BA.4-5, BA.4.6, BA.2.75, BJ.1 and BQ.1.1
This post is in response to a couple of recent posts highlighting concerning changes in the...
Vaccine taking
Someone, and I can't remember who, said, possibly, sarcastically, that we should do as we are told,...
Important SARS-CoV-2 and Covid-19 information for Chronic Lymphocytic Leukaemia/CLL patients
This post, prepared in collaboration with @[52122] , draws together some earlier posts...
Concern About New Recommendations to Relax COVID-19 Prevention Measures
This was on the Medscape site earlier today. (I've not copied the whole article).
The Government...
Related Posts
- Scenarios for ending lockdown and how this will impact on those with CLL
What do all these Vaccine Efficacy Numbers that they quote actually mean?- A Comparison of between Covid-19, a Cold, the Flu, Hay Fever and Asthma plus other Coronavirus updates
CLL Society’s COVID-19 Update for the Week of November 7th, 2022
Rare COVID-19 vaccine complication linked to circulating spike protein in blood
